Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Prostatic Neoplasms 56Breast Neoplasms 7Bulbo-Spinal Atrophy, X-Linked 4Neoplasms 3Neoplasm Metastasis 3Triple Negative Breast Neoplasms 2Salivary Gland Neoplasms 2Stage I Prostate Adenocarcinoma 1Recurrence 1Paget Disease, Extramammary 1PSA Level Greater Than Two 1Ovarian Neoplasms 1Non-Muscle Invasive Bladder Neoplasms 1Lower Urinary Tract Symptoms 1Gynecomastia 1Fallopian Tube Neoplasms 1Erectile Dysfunction 1Carcinoma, Transitional Cell 1Carcinoma, Ovarian Epithelial 1Breast Neoplasms, Male 1Adenocarcinoma 1

Interventions

Specimen Handling 2Nivolumab 2toripalimab 1talimogene laherparepvec 1bicalutamide 1Magnetic Resonance Spectroscopy 1Ipilimumab 1Fluorescein 1CTLA-4 Antigen 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Paget Disease, Extramammary × bicalutamide × Clear all
NCT07117851 2025-08-12

A Study of Disitamab Vedotin + Bicalutamide in HER2/AR-Positive Scrotal Paget's Disease

Fudan University

Phase 2 Recruiting
20 enrolled

Paget Disease, Extramammary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡